Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kaplan-Meier Approach01:24

Kaplan-Meier Approach

498
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
498
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

322
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
322
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

664
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
664
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

494
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
494
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

497
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
497
Censoring Survival Data01:09

Censoring Survival Data

458
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
458

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inter-institutional heterogeneity in high-volume esophageal cancer centers: an ancillary study of JCOG1109 (JCOG2308A).

Esophagus : official journal of the Japan Esophageal Society·2026
Same author

Definitive IMRT alone with reduced prophylactic nodal irradiation for Early-Stage Oropharyngeal Cancer: JCOG1208.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Oncologic Safety of Omitting Mediastinal Lymph Node Dissection in Segmentectomy for Ground-Glass Opacity-Dominant Lung Cancer: A Supplementary Analysis of JCOG1211.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026
Same author

A multicenter randomized phase III trial of weekly cisplatin chemoradiotherapy versus radiotherapy in elderly patients with head and neck squamous cell carcinoma unfit for high-dose cisplatin: JCOG2405 (ELDER-WEEKLY).

Japanese journal of clinical oncology·2026
Same author

A Randomized Controlled Phase 3 Trial of Oral Prednisolone Administration Versus Local Triamcinolone Injection Therapy for Esophageal Stricture Prevention After Extensive Endoscopic Submucosal Dissection (JCOG1217).

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society·2026
Same author

A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART).

Japanese journal of clinical oncology·2026
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Related Experiment Videos

[Time-to-event endpoints--definitions and methodological issues].

Akihiro Sato1, Naoki Ishizuka, Haruhiko Fukuda

  • 1Cancer Information and Epidemiology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 27, 2003
PubMed
Summary
This summary is machine-generated.

Accurate time-to-event analysis in cancer research requires understanding event definitions, censoring, and competing risks. This guide clarifies major endpoints like overall survival and progression-free survival for unbiased estimates.

Related Experiment Videos

Area of Science:

  • Clinical research methodology
  • Biostatistics
  • Oncology

Context:

  • Time-to-event endpoints are crucial in clinical cancer research.
  • Accurate estimation of survival time is essential for evaluating treatment efficacy.
  • Understanding biases from competing risks and censoring is vital.

Purpose:

  • To define and characterize major time-to-event endpoints used in cancer research.
  • To highlight potential pitfalls and biases associated with these endpoints.
  • To provide guidance for obtaining unbiased estimates of survival and event times.

Summary:

  • This review details standard definitions and characteristics of key time-to-event endpoints, including overall survival (OS), progression-free survival (PFS), relapse-free survival (RFS), disease-free survival (DFS), and time to treatment failure (TTF).
  • It emphasizes the critical importance of precise event definition, appropriate handling of censoring, and awareness of competing risks to prevent biased results.
  • The authors discuss common challenges and pitfalls encountered in the application and interpretation of these survival metrics.

Impact:

  • Enhances the rigor and reliability of clinical cancer trial data interpretation.
  • Facilitates more accurate comparisons of treatment effectiveness across studies.
  • Improves the understanding and application of survival analysis in oncology research.